Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT04595266 |
Title化疗栓塞（Lifepearls-伊立替康）在结直肠癌和转移性疾病患者中的应用 | 阶段
第二阶段
|
Date Added 2020-10-20 |
地点
西班牙
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Anti-EGFR or Bevacizumab, FOLFOX regimen, LIVERPEARLS-Irinotecan |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04589845 |
Title肿瘤诊断精准免疫肿瘤学和体细胞靶向合理性（TAPISTRY）平台研究 | 阶段
第二阶段
|
Date Added 2020-10-19 |
地点
Alabama, United States
Arizona, United States California, United States Colorado, United States Delaware, United States Florida, United States Georgia, United States Idaho, United States Illinois, United States Indiana, United States Maine, United States Maryland, United States Michigan, United States Minnesota, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States 澳大利亚 比利时 巴西 加拿大 中国 丹麦 法国 德国 香港 以色列 意大利 日本 大韩民国 新西兰 波兰 葡萄牙 波多黎各 新加坡 南非 西班牙 瑞士 台湾 英国 |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
招聘
|
药物
Alectinib, Atezolizumab, Belvarafenib, Entrectinib, Idasanutlin, Inavolisib, Ipatasertib, Pralsetinib, Trastuzumab emtansine |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04591431 |
TitleThe Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | 阶段
第二阶段
|
Date Added 2020-10-19 |
地点
意大利
|
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Alectinib, Atezolizumab, Brigatinib, Cobimetinib, Entrectinib, Erlotinib, everolimus, Ipatasertib, Ipilimumab, Itacitinib, Lapatinib, Nivolumab, Oncology Drugs, palbociclib, Pemigatinib, Pertuzumab, Ponatinib, Trastuzumab, Trastuzumab emtansine, Vemurafenib, Vismogedib |
标签
MSS/ MMRp
|
| NCT ID NCT04575922 |
TitleNivolumab+Ipilimumab+RT in MSS mCRC | 阶段
第二阶段
|
Date Added 2020-10-05 |
地点
Massachusetts, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Ipilimumab, Nivolumab |
标签
MSS/ MMRp
|
| NCT ID NCT04550897 |
Title结直肠癌患者使用 BM7PE 免疫毒素的 I/II 期研究 | 阶段
第 1 阶段
|
Date Added 2020-09-16 |
地点
挪威
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
BM7PE |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04535024 |
TitleThe Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal Cancer | 阶段
第二阶段
|
Date Added 2020-09-01 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Sintilimab |
标签
MSS/ MMRp
|
| NCT ID NCT04483219 |
TitleTyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma. | 阶段
第二阶段
|
Date Added 2020-07-23 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
Unknown status
|
药物
TKI ± anti-PD-1 antibody |
标签
MSS/ MMRp
|
| NCT ID NCT04444622 |
TitleImmunotherapy for Third Line Metastatic Colorectal Cancer | 阶段
第二阶段
|
Date Added 2020-06-23 |
地点
Florida, United States
Michigan, United States New Jersey, United States New York, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物 |
标签
MSS/ MMRp
|
| NCT ID NCT04432857 |
TitleAN0025 and Pembrolizumab Combination in Advanced Solid Tumors | 阶段
第 1 阶段
|
Date Added 2020-06-16 |
地点
Missouri, United States
Texas, United States Utah, United States Virginia, United States 法国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
AN0025, Pembrolizumab |
标签
MSS/ MMRp
|
| NCT ID NCT04426669 |
Title利用 CRISPR 基因工程抑制编码细胞内免疫检查点 CISH 基因的肿瘤浸润淋巴细胞治疗转移性胃肠癌的研究 | 阶段
Phase 1, Phase 2
|
Date Added 2020-06-11 |
地点
Minnesota, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Aldesleukin, Cyclophosphamide, Fludarabine, Tumor Infiltrating Lymphocytes (TIL) |
标签
MSI-H/ MMRd, MSS/ MMRp
|
